Development of novel nanoparticle based PLK1, EGFR, and PD-L1 targeted therapies for lung cancer Public Deposited

Non-small cell lung cancer (NSCLC) is the deadliest form of cancer and represents nearly a fourth of all cancer related deaths worldwide. Identifying molecular targets and developing effective therapeutic regimens to improve NSCLC treatments and patient quality of life is needed. Nanoparticles possess unique properties to enhance treatment efficacy and reduce toxic side effects of traditional therapies. In my dissertation, I exploited versatile mesoporous silica nanoparticles (MSNP) to improve radiation therapy and immunotherapy, which are two key treatments for NSCLC patients.

Creator
Degree
Department
Institution
School
Publisher
Identifier
  • 10.6083/n583xv58g
  • moataz.reda.2019.pdf
Keyword
Date
  • 2019
Document type
Citation
  • Reda, M. "Development of novel nanoparticle based PLK1, EGFR, and PD-L1 targeted therapies for lung cancer" (2019). OHSU Digital Collections. https://doi.org/10.6083/n583xv58g
In Collection:
In Administrative Set:

Items

Downloadable Content